Please select the eligibility criteria that correspond to the clinical trial below.
Title: Rapid Identification and Susceptibility Testing of Pathogens Growing in Blood Culture Bottles - A Quality Improvement Theragnostic Stewardship Project
Brief Summary: Would rapid identification of bacteria and rapid detection of methicillin-resistant S. aureus (MRSA) and vancomycin-resistant enterococci (VRE) (using an FDA-cleared assay) in positive blood culture bottles improve patient care at Mayo Clinic Rochester (or just lead to increased cost)?


Options:
A: Inclusion Criteria:

* Age≥ 18 years
* Written signed and dated inform consent
* First time with fever observed in a neutropenic patient
* Severe sepsis in a patient hospitalized in ICU
* Suspicion of infective endocarditis
* Microbial investigation from Monday to Friday

Exclusion Criteria:

* Not affiliated to Health Insurance (social security)
* Included in another interventional trial testing microbial DNA detection during the time "without Septifast®"
* Included in another clinical trial for which the clinician assumes that it will not be possible to prescribe an anti-infectious therapy adequately to microbial detection in the blood
* Patient previously included in the protocol
* Sepsis with a microbial diagnosis
B: Inclusion criteria:

* Positive blood culture during the study period.
* No positive blood cultures in prior 7 days
* Minnesota state research authorization provided

Exclusion criteria:

* No Minnesota state research authorization
* Deceased or transitioned to comfort care within 24 hours of enrollment
* Positive blood culture in prior 7 days
* Previously enrolled in this study
* Negative Gram stain
C: Inclusion Criteria:

* ICU patients ≥18 years.
* With a suspected pneumonia (according to CPIS definition), primary blood-stream infection (according to CDC definition), and/or urinary tract infection (according to IDSA Guidelines).
* And presence of ≥2 GNB/field on direct examination of a respiratory sample (quantitative bronchial aspirate with an available volume ≥ 1mL), urinary sample or blood culture.
* Leading to an empirical carbapenem prescription, not administered for more than 6 hours when considering the inclusion of the patient.
* Written informed consent signed by the patient / the trustworthy person / the next-of-kin / close relative, or inclusion in case of emergency and written informed consent will been signed by the patient as soon as possible.
* Patients affiliated to French social security.

Exclusion Criteria:

* Pregnancy.
* Allergy to beta-lactams.
* Patients already treated with ongoing carbapenems for another documented infection, blocking carbapenem de-escalation.
* Patients included in another interventional study.
* Patients in whom a procedure of withdrawing life-sustaining treatment was decided before inclusion.
* Moribund patients.
* Patients with aplasia.
* Patients under tutorship/curatorship or patient deprived of freedom
D: Inclusion Criteria:

* adults 18 years or older with community onset abscess

Exclusion Criteria:

* previous treatment for same abscess in past 14 days
* postoperative infection
* inability to provide informed consent

Answer: B